1. Pink Sheet

‘Reckless’ State Campaigns Seek To Undermine Western COVID-19 Vaccines

 
• By Alaric DeArment

China, Iran and especially Russia have launched campaigns aimed at undermining confidence in Western vaccines, especially Pfizer’s, according to two reports.

Russia map close up with magnifier
Reports highlighted state-led campaigns by Russia, China and Iran to undermine Western-developed COVID-19 vaccines. • Source: Shutterstock

State-backed propaganda campaigns – particularly from Russia, China and Iran – have sought to inject false or misleading narratives into the information ecosystem with the aim of undermining public confidence in Western-developed vaccines against COVID-19, according to new reports. But the best option for the biopharma industry is to stick to what it has been doing, Biotechnology Innovation Organization chairman Jeremy Levin said.

“The only thing that biotechnology companies can do is adhere to the principles of transparency and publication and peer review, coupled with a commitment to science and excellence,” he said in an interview with Scrip

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

EU Pharma Reform: Exclusivity Vouchers Alone Are Insufficient Incentive For Antimicrobials, Industry Says

 
• By Eliza Slawther

European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.

Trump Administration Push For Dismissal, Transfer Of Mifepristone Case Leaves Overhang For Pharma

 
• By Sarah Karlin-Smith

The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.

Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By Sue Sutter

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.